ANG Lifesciences India Ltd.
BBSE:ANG34.15
INR
-1.79
(-4.98%)
ISIN
INE236W01016
Return %
Stock
S&P 500
1Y
8.76
14.20
3Y
-51.07
81.12
5Y
-90.89
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Rajesh Gupta
- Full Time Employees
- 379
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Darbara Complex, SCO 113 Amritsar India 143001
- IPO Date
- Sep 8, 2017
- Website
- anglifesciences.com
- Similar Companies
- Business
- ANG Lifesciences India Limited manufactures and markets finished pharmaceutical formulations primarily in sterile dry powder injectable vials, along with liquid injections, tablets, capsules, syrups, ointments, and creams; its core products encompass antibiotics such as cephalosporins (generations I through IV), penicillins, glycopeptides like vancomycin, carbapenems like faropenem sodium, and beta-lactamase inhibitors including sulbactam; antiulcer agents such as pantoprazole and omeprazole; antivirals like acyclovir; antimalarials; corticosteroids; analgesics including paracetamol and aceclofenac; and nutritional supplements like multivitamins, calcium, phosphorus, and digestive enzymes. The company offers dry powder injections (e.g., vancomycin, sulbactam, pantoprazole, ampicillin), liquid injections (e.g., paracetamol, amikacin sulphate, dopamine hydrochloride), hard gelatin capsules (e.g., domperidone, rabeprazole, amoxycillin, cephalexin), beta-lactam tablets (e.g., cefixime, cefpodoxime, cefuroxime), standard tablets (e.g., cetirizine, aspirin gastro-resistant), liquid suspensions/syrups (e.g., aceclofenac-paracetamol), soft gelatin capsules (e.g., zinc oxide, alfacalcidol), and topical creams/ointments (e.g., clotrimazole, ciprofloxacin). Incorporated in 2006 and headquartered in Amritsar, Punjab, India, with manufacturing facilities in Baddi, Himachal Pradesh, ANG Lifesciences operates in domestic institutional, third-party manufacturing, direct marketing, and export markets across India and internationally, serving clients such as Gland Pharma, Hetero Healthcare, and Hexamed Lifesciences; it also provides printing and packaging solutions including mono cartons and blister foils through backward integration via its acquisition of Mansa Printers & Publishers Limited in April 2021. In recent developments, the company completed the acquisition of two formulation manufacturing facilities (Units 3 and 4) from Ind-Swift Limited in Baddi, Himachal Pradesh, for INR 60 crore through internal accruals and deferred bank funding by mid-2024, renaming them as Unit 5 and Unit 6 to scale production capacity for rising domestic and export demand; earlier, it acquired Star Biotech's assets in 2019 for additional tablet and capsule lines, invested in a 10% stake in Renatus Meditech Solutions as a seed investor, and enhanced dry powder vial capacity post its 2017 IPO from 70 million to 140 million units by 2018. These expansions position ANG Lifesciences as a comprehensive healthcare solutions provider with over 100 products in major therapeutic categories, supported by WHO GMP-certified, cGMP-compliant facilities focused on quality injectables and formulations.